Physician profile
Bashar Katirji
NPI 1700808011
$9,217.71
in general payments reported to CMS, 2019-2025
34 companies · $2,702 in 2025
The $2,702 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $195 · 2021: $192 · 2022: $732 · 2023: $1,989 · 2024: $1,408 · 2025: $2,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,015 · Honoraria: $1,000 · Education: $83.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,014.57 |
| Honoraria | $1,000.00 |
| Education | $83.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nihon Kohden America, LLC | $1,500.00 | 2019 | |
| Natus Medical Incorporated | $1,016.35 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $995.83 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $787.86 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $719.01 | 2020-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Ucb, INC. | $713.67 | 2023-2025 | Zilbrysq, Rystiggo |
| Argenx US, INC. | $678.66 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $388.27 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.52 | 2022-2025 | Hyqvia |
| Genzyme Corporation | $236.81 | 2019-2024 | |
| Grifols USA, LLC | $231.63 | 2019-2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals Lp | $220.74 | 2024-2025 | Wainua |
| Janssen Scientific Affairs, LLC | $148.99 | 2025 | |
| Biogen, INC. | $146.75 | 2022-2025 | Spinraza, Tysabri, Vumerity |
| Alnylam Pharmaceuticals INC. | $144.10 | 2025 | Onpattro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $139.86 | 2019-2022 | |
| Celgene Corporation | $104.14 | 2021-2022 | |
| Averitas Pharma INC. | $87.16 | 2023-2025 | Qutenza |
| Pfizer INC. | $86.80 | 2019-2025 | |
| Abbvie INC. | $85.92 | 2023-2025 | |
| Tg Therapeutics, INC. | $84.33 | 2023-2025 | |
| Janssen Biotech, INC. | $77.39 | 2025 | |
| Amgen INC. | $59.98 | 2025 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $52.54 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $44.45 | 2025 | Keveyis |
| Emd Serono, INC. | $38.91 | 2023 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $35.69 | 2019 | |
| Advanced Respiratory, INC | $32.18 | 2019 | |
| Lundbeck LLC | $28.64 | 2019 | |
| Invivyd INC | $20.52 | 2025 | Pemgarda |
| Lilly USA, LLC | $19.08 | 2025 | Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $15.40 | 2025 | Daybue |
| Otsuka America Pharmaceutical, INC. | $14.63 | 2024 | Nuedexta |
| Janssen Pharmaceuticals, INC | $10.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Katirji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.